ArticleOncogene2025
HDAC1/2-mediated deacetylation of KLF9 promotes the malignant progression of nasopharyngeal carcinoma via CDH17.
Article in Oncogene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Histone deacetylases: Function in tumor development and therapeutic prospects (Review).Oncology letters · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Protein acetylation modifications play an important role in the malignant progression and metastasis of tumors. The transcription factor KLF9 primarily functions as a transcriptional suppressor exerting anticancer effects in some tumors. However, the expression regulation of KLF9 and its role in nasopharyngeal carcinoma (NPC) are not well understood. In the present study, we found that KLF9 exhibited deacetylation and low expression in NPC, and its overexpression inhibited the proliferation and metastasis of NPC. Mechanistically, the high expression of HDAC1/2 in tumor cells mediated the deacetylation of KLF9 at lysine 237/238, further inhibiting the K63 ubiquitination induced by the E3 ubiquitin ligase SYVN1, thus reducing the protein stability and subsequent transcriptional inhibition function of KLF9. Meanwhile, we found that KLF9 could restrain the transcription and expression of cadherin-17 (CDH17), suppressing the malignant progression and metastasis of NPC. This research expands our comprehension of transcription factor expression regulation from the perspective of protein acetylation and ubiquitination interactions, providing novel molecular markers and therapeutic targets for NPC.
Indexed as
Identifiers
40615689What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.